3 ASX shares at 52-week lows: Are they in the bargain bin?

While the Aristocrat Leisure Limited (ASX: ALL) share price may be going gangbusters this month and climbing to an all-time high, not all shares have fared so well.

In fact, the three shares below have just fallen to 52-week lows. Are they in the bargain bin now?

The Compumedics Limited (ASX: CMP) share price has fallen a massive 61% this year and currently sits at a 52-week low of 33 cents. The medical equipment company’s shares came under heavy selling pressure in February after it posted its half-year results. A shortfall in sales in the United States led to a 50% drop in EBITDA to $1.2 million. This was especially disappointing considering management had previously stated that it expected EBITDA growth of 20% in FY 2017. While Compumedics is an interesting company with a lot of promise, I would hold off an investment until there are signs of improvement.

The Mayne Pharma Group Ltd (ASX: MYX) share price continued its decline last week and sunk to a 52-week low of 99 cents. Incredibly this means its shares have lost 34% of their value since the day before the company announced its acquisition of 37 approved and five FDA-filed products from Teva Pharmaceutical Industries and Allergan for US$652 million last year. Concerns that President Trump may shake up the industry by forcing significant price cuts on generic drugs appears to be behind the slump. Whilst I’m a big fan of Mayne Pharma and think the company has a number of valuable assets, until Trump’s plans are finalised I would suggest investors avoid the company’s shares.

The Yowie Group Ltd (ASX: YOW) share price fell to a multi-year low of 29 cents on Friday of last week. Weaker-than-expected sales in the U.S. and news that it is likely to go to trial for an alleged breach of its manufacturing agreement have weighed heavily on its shares. While the confectionery company could prove to be a bargain buy at the current share price, I would suggest investors wait for an improvement in its sales performance and also the outcome of the aforementioned trial.

Finally, while Compumedics, Mayne Pharma, and Yowie may not be in the buy zone, in my opinion these quality shares certainly are.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.